The QualityStocks Daily Wednesday, December 4th, 2019

Today's Top 3 Investment Newsletters

SmallCapRelations (CLWD) +152.17%

StocksToBuyNow (GWPD) +150.00%

StockMarketWatch (PTGX) +72.92%

The QualityStocks Daily Stock List

Amazing Energy Oil and Gas, Co. (AMAZ)

Investor Place, PR Newswire, Proactive Investors, Energy Voice, Oil and Gas Investments Bulletin, Money Morning and Tech Know Bits reported earlier on Amazing Energy Oil and Gas, Co. (AMAZ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Amazing Energy Oil and Gas, Co. engages in the exploration, development, and production of oil and gas in Texas and East New Mexico. It operates leaseholds in the Permian Basin where it holds the rights within a 70,000-acre leasehold in Pecos County, Texas and is surrounded by large independent oil and gas companies. In addition, the Company provides oilfield services to oil and gas well owners. The independent oil and gas exploration and production Company has its head office in Plano, Texas. Amazing Energy Oil and Gas lists on the OTC Markets’ OTCQX.

Jilpetco is a wholly-owned subsidiary of Amazing Energy Oil and Gas. Jilpetco is an oilfield services company. It owns and operates drilling, completion, and workers rigs. Jilpetco also leases operational services equipment.

Amazing also holds 16,904 gross acres in Lea County, New Mexico that is held by production. The Company chiefly engages in the acquisition and exploitation of oil and natural gas properties with a focus on well-defined plays containing stacked pay zones such as the San Andres, Devonian, Pennsylvanian and Wolfcamp.

Regarding Pecos County, Amazing’s position accounts for rights within 70,000 acres leasehold (roughly 100 sq. miles); 100 percent WI; 75 percent Net Revenue Interest (NRI). A total of 26 wells have been drilled on the property. These are either producing or in the process of being completed.

In West Sawyer, Lea County, New Mexico, Company development highlights include 16,904 gross acres; 10,051 net acres; 56 percent average Working Interest (WI) and operatorship. Four horizontal wells have been drilled. Net Production = 32.4 BOPD.

In November, Amazing Energy Oil and Gas announced that it closed on a $4,500,000 financing package and at the same time acquired assets located in Walthall County, Mississippi known as the Denver Mint Project. The new assets comprise 900 acres of leasehold, 9 oil wells and a saltwater disposal well. The assets include associated production facilities and infrastructure essential to considerably increase the asset's present production profile.

Today, Amazing Energy Oil and Gas announced that Company Management will be presenting at the LD Micro Main Event (XII) on Tuesday, December 10, 2019 at 11:40 AM PST. The LD Micro Main Event (XII) will take place December 10th-12th in Los Angeles, California at the Luxe Sunset Bel Air Hotel, and will feature 275 companies and will be attended by more than 1,400 individuals.

Amazing Energy Oil and Gas, Co. (AMAZ), closed Wednesday's trading session at $0.15, even for the day, on 144,100 volume with 17 trades. The average volume for the last 3 months is 35,603 and the stock's 52-week low/high is $0.000099999/$0.400000005.

chart

Apple Rush Company, Inc. (APRU)

TipRanks, Market Wire News, Stockwatch, Wall Street Analyzer, GlobeNewswire, Penny Stock Base, Wallet Investor, Stockhouse, Morningstar, Investing.com, MarketPlace.org, Financial Buzz, MarketWatch, InvestorsHub, and Investors Hangout reported beforehand on Apple Rush Company, Inc. (APRU), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Apple Rush Company, Inc., by way of its subsidiary APRU, LLC, is a distributor of CPG (Consumer Packaged Goods )products under the trademarked Apple Rush brand and other labels. The Apple Rush brand has greater than four decades of existence in the natural beverage industry. The Company develops, bottles, markets, distributes, and sells an array of beverages and snacks to wholesale and retail clients in the United States. Formed in 1998, Apple Rush Company lists on the OTC Markets.

Apple Rush Company is an historical leader in the organic and natural beverage sector. The Company offers organic sparkling juice blended beverages, with apple juice as the base under the brand name Apple Rush. In addition, its goal is to become the leader in the distribution of anhydrous hemp oil products nationwide.

Subsidiary APRU, LLC focuses on the development and sales of all natural Apple Rush sparkling juices, and research and development (R&D) of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives and other active ingredients including the Company’s exclusive agathos active, kratom, kava, blue lotus, and ginseng.

The Apple Rush Company’s proprietary all natural CBD (cannabidiol) emulsion has been put into the production of Lickinghole Creek’s One Lion 16 ounce sparkling water. Lickinghole Creek Craft Brewery is a farm brewery growing hemp, hops, as well as barley. It brews world class beer on 300 acres in the heart of the State of Virginia.

Last week, The Apple Rush Company provided an update for 2020 via a letter to shareholders. Mr. Tony Torgerud, Chief Executive Officer of Apple Rush, stated, “We have been quiet the last couple of months while preparing for the explosive growth plans for Apple Rush in 2020. This growth includes an operational plan that will expand distribution to the entire country and to several International locations as well. We have spent an enormous amount of time and energy working with our team to build the foundation for the future.”

Apple Rush Company, Inc. (APRU), closed Wednesday's trading session at $0.0105, up 0.961538%, on 1,949,516 volume with 35 trades. The average volume for the last 3 months is 1,155,057 and the stock's 52-week low/high is $0.004699999/$0.024.

chart

Cornerstone Capital Resources, Inc. (CTNXF)

Penny Stock Hub, 24hgold, Streetwise Reports, OTC Markets, The Stock Market Watch, Geology for Investors, Stockhouse, Investing News, Dividend Investor, Mining Feeds, Junior Mining Network, Wallet Investor, GuruFocus, TradingView, Resource World, News Scanner, Wallmine, Investing.com, MarketWatch, Seeking Alpha, Investors Hangout, GlobeNewswire, and Morningstar reported beforehand on Cornerstone Capital Resources, Inc. (CTNXF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Cornerstone Capital Resources, Inc. is a mineral exploration company listed on the OTC Markets. The Company has a diversified portfolio of projects in Ecuador and Chile. This includes in the Cascabel gold-enriched copper porphyry joint venture (JV) in northwest Ecuador – 15 percent interest. Established in 1997, Cornerstone Capital Resources is based in Ottawa, Ontario.

The Company takes advantage of its own exploration funding via JV and strategic partnerships. Cornerstone Capital Resources has its minority financed interest in the Cascabel copper gold project in northern Ecuador. There, drilling is ongoing and numerous high-priority porphyry centers are currently recognized within the project.

Cornerstone has a 22.8 percent direct and indirect interest in Cascabel consisting of a direct 15 percent interest in the project financed through to completion of a Feasibility Study (FS) and repayable out of the Company’s share of project cash flow, plus an indirect interest consisting of 9.2 percent of the shares of JV partner and project operator SolGold Plc.

In Chile, The Miocene project, held by Cornerstone Capital Resources’ Chilean subsidiary, Minera Cornerstone Chile Limitada (MCCL), is situated in the Regions of Atacama and Antofagasta of northern Chile. It is targeting epithermal gold-silver and porphyry gold-copper deposits along the interpreted northern extension of the Maricunga magmatic belt that hosts a number of world-class gold deposits.

Yesterday, Cornerstone Capital Resources provide an update on its Bramaderos gold and copper project in southern Ecuador that it is exploring together with ASX listed Sunstone Metals, Inc. under a farm-in agreement. Selected highlights include Limon - Assay results from drill hole LMDD004 indicate that drilling is now close to a gold-copper porphyry center. Furthermore, Assays include 40m1 at 0.1g/t gold, 0.12% copper and 19ppm molybdenum, from 863m down hole. This indicates drilling is within the outer halo of a mineralized porphyry gold-copper system of major scale.

At the Bramaderos Main target, drill holes BMDD004 and BMDD005 have recently been completed. Assays are pending and are expected in January 2020. Both have intersected wide intervals containing copper mineralization as chalcopyrite.

Cornerstone Capital Resources, Inc. (CTNXF), closed Wednesday's trading session at $1.7993, even for the day, on 100 volume. The average volume for the last 3 months is 1,978 and the stock's 52-week low/high is $0.034000001/$3.60999989.

chart

Fuling Global, Inc. (FORK)

Zacks, Stock Twits, MacroTrends, StockInvest.us, Market Chameleon, Street Insider, PR Newswire, Super Stock Screener, Infront Analytics, Nasdaq, Seeking Alpha, Investing.com, Morningstar, MarketBeat, Simply Wall St and MarketWatch reported earlier on Fuling Global, Inc. (FORK), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Fuling Global, Inc. manufactures and distributes plastic and paper serviceware for the foodservice industry. The Company has precision manufacturing facilities in the United States, Mexico and China. Fuling Global sells its products directly, and also by way of distributors to dealers, QSRs (Quick Service Restaurants), manufacturers, and retailers. Established in 2015, Fuling Global is headquartered in Wenling, the People's Republic of China (PRC).

Fuling Global’s plastic and paper serviceware products include disposable cutlery, drinking straws, cups, plates and other plastic and paper products. These products are used by over 100 customers mainly from the U.S., China and Europe, including Subway, Wendy's, Burger King, Taco Bell, KFC (China only), Walmart, and McKesson.

Presently, Fuling Global has four factories in China and one in the United States with greater than 1,500 employees. The yearly production capacity is approximately 50,000 tons including GPPS,PS,PP,PLA,PET.

Recently, Fuling Global announced financial results for the six months ended June 30, 2019. Revenues increased by 6 percent to $70.9 million for the first half of 2019, from $66.8 million for the comparable period the year prior. Gross Profit for the first six months of 2019 grew by 61 percent to $16.7 million, from $10.4 million for the same period last year.

Net income from Continuing Operations rose sharply to $7.4 million, or $0.47 per share, versus $0.9 million, or $0.06 per share, for the first half of 2018. Net Income Attributable to Fuling Global was $7.7 million, or $0.49 per share, for the first half of 2019, versus $0.4 million, or $0.02 per share, for the same period the year prior.

Furthermore, recently, Xinfu Hu, Chief Executive Officer of Fuling Global, stressed the importance of environmental protection in the foodservice sector while addressing the 23rd annual China Fast Food Industry conference, held in October 2019 in Dalian, China. Hu's speech, titled, "Recycling, Benefiting the Earth -- International Tableware Environmental Protection Solution," centered on developing and implementing environmentally friendly solutions in the foodservice industry, including the use of completely biodegradable and recyclable products.

Fuling Global, Inc. (FORK), closed Wednesday's trading session at $2.44, up 0.972481%, on 5,794 volume with 59 trades. The average volume for the last 3 months is 5,476 and the stock's 52-week low/high is $1.87/$4.28999996.

chart

International Spirits & Wellness Holdings, Inc. (ISWH)

Spotlight Growth, OTC Markets, Market Screener, NewMediaWire, Undergroundstocks, Investor Ideas, Investor News, Financial Buzz, and Stock News Feed reported previously on International Spirits & Wellness Holdings, Inc. (ISWH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

International Spirits & Wellness Holdings, Inc. (ISWH) is a top-tier brand incubator in the Global Wine & Spirits and CBD-Infused Products and Home Healthcare markets. It is an authorized importer, licensor, and marketer of premium beverage brands, with sales of inventive products and brands worldwide. The Company previously went by the name International Spirits & Beverage Group, Inc. It changed its corporate name to International Spirits & Wellness Holdings, Inc. in July of this year. ISWH is Nevada based.

The Company develops and grows brands through all phases. This includes concept creation, product development, market positioning, and sales and marketing. ISWH’s objective is to be an international innovation leader within the alcohol beverage and cannabis industries. It will source early stage brands, existing brands with unrealized potential, and create in-house brands that raises innovation and expectations with trade and consumers. Furthermore, ISWH has partnered with Bengala Technologies to develop and commercialize enterprise and B2B (Business-to-Business) software technology products targeting the logistics and supply-chain marketplace.

ISWH’s Wine and Spirit portfolio is led by Besado Tequila. This is its unique entrance within the growing ultra-premium tequila segment. In addition, ISWH’s Dziaq (dee-zee-ack) Liqueur re-brand to a wine based ready-to-serve cocktail line allows for substantially more distribution channels (2 x spirit based alternatives).

ISWH’s latest brand is P19, which is its first entrance into the CBD (cannabidiol) space. It partnered with best-in-class CBD experts at BioPulse Labs. P19 was created around developing the finest CBD products such as gummies, topicals, tinctures, and more.

In November, ISWH announced an upcoming agreement for the appointment of an exclusive manufacturing and marketing partner for the launch of five CBD-based wellness products. This will include a comprehensive branding refresh for its P19 CBD-based products brand. According to terms so far established, the Partner will provide ISWH with procurement of five trademarks, five brand custom websites (each with online sales and payment processing system), five brand social platforms (namely Facebook, Instagram, and Twitter), and five brand POP, POS sales & marketing guides.

International Spirits & Wellness Holdings, Inc. (ISWH), closed Wednesday's trading session at $0.0003, even for the day, on 32,847,563 volume with 21 trades. The average volume for the last 3 months is 34,586,089 and the stock's 52-week low/high is $0.000199999/$0.0163.

chart

NervGen Pharma Corp. (NGENF)

Stock Target Advisor, TipRanks, Investor Ideas, InvestorX, Lamp News, Market Screener, Investors Hangout, Stockhouse, MarketWatch, PR Newswire, and Trading View reported previously on NervGen Pharma Corp. (NGENF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NervGen Pharma Corp. is a regenerative medicine company listed on the OTC Markets Group’s OTCQX. The Company’s commitment is to creating leading-edge solutions for the treatment of nerve damage. This includes spinal cord and peripheral nerve injury. The Company’s lead compound is NVG-291. NervGen Pharma has its corporate headquarters in Vancouver, British Columbia.

NervGen’s core technology targets protein tyrosine phosphatase sigma (PTPσ). This is a neural receptor that impedes nerve regeneration. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for diverse medical conditions. Research has been conducted on other applications of PTPs including MS, stroke, cardiac arrhythmia, and Alzheimer’s Disease.

In addition, the Company continues to research secondary applications including multiple sclerosis, acute myocardial infarction induced arrhythmia (AMI, normally known as a heart attack), stroke and other neurodegenerative diseases. NervGen’s plan is to begin a Phase 1 human clinical trial for its lead compound, NVG-291, in early 2020 under an Investigational New Drug application with the US Food and Drug Administration (FDA).

NervGen Pharma is advancing NVG-291 for the treatment of spinal cord injury as it believes this indication is a significant opportunity due to the present lack of non-surgical solutions in the market, the considerable impact on quality of life, and the high cost burden to the healthcare system. The Company’s belief is that NVG-291 as a therapy could alleviate or improve upon the symptoms and conditions associated with spinal cord injury. It also believes that NVG-291 as a therapy could empower these patients to live more active and productive lives.

Recently, NervGen Pharma announced a research initiative to advance its proprietary therapeutic technology platform, now in development for spinal cord injury and multiple sclerosis, to generate new treatments for Alzheimer's disease (AD). Moreover, NervGen Pharma recently announced the appointment of Mr. Paul Brennan to the position of President & Chief Executive Officer effective immediately. He replaces Dr. Ernest Wong who will continue to formally support NervGen as a consultant.

Mr. Brennan has also been appointed as a member of the Company’s Board of Directors. NervGen also announced the appointment of Mr. Lloyd Mackenzie in the newly created position of Chief Operating Officer, effective immediately.

NervGen Pharma Corp. (NGENF), closed Wednesday's trading session at $1.07, even for the day, on 1,999 volume with 6 trades. The average volume for the last 3 months is 18,439 and the stock's 52-week low/high is $0.648800015/$1.72000002.

chart

Salt Lake Potash Limited (WHELF)

All Stocks Today, Proactive Investors, Macroaxis, 4-Traders, Street Insider, Wallet Investor, Dividend.com, InvestorsHub, Morningstar, Dividend Investor, MarketWatch and Nasdaq reported earlier on Salt Lake Potash Limited (WHELF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Salt Lake Potash Limited’s vision is to build the most sustainable, most rewarding fertilizer project in the world. The Company plans to produce premium, organic Sulphate of Potash (SOP) from salt lakes in Western Australia. SOP is the premium source of potassium (macro-nutrient) favoured by high value, chloride intolerant crops. Salt Lake Potash engages in the exploration and development of resource projects in Australia. The Company previously went by the name Wildhorse Energy Limited. It changed its name to Salt Lake Potash Limited in November of 2015. Salt Lake Potash has its corporate office in Perth, Australia.

The Company is developing the Goldfields Salt Lakes Project. An initial 50,000tpa Demonstration Plant will provide the template for a very large scale, very long life, and very economic project across several salt lakes, delivering premium, organic nutrients to the world’s farmers.

Salt Lake Potash plans to produce the premium product Sulphate of Potash (SOP) from extracting hypersaline brine from salt lakes, transporting the brine in a series of solar evaporation ponds to produce potassium-rich harvest salts that can subsequently easily be converted in SOP for the domestic and worldwide markets.

The long term plan of Salt Lake Potash Limited is to develop an integrated SOP operation, producing from a number (or all) of the lakes within the Goldfields Salt Lakes Project, after confirming the technical and commercial elements of the Project through construction and operation of the above-mentioned Demonstration Plant.

The nine salt lakes that make up the Goldfields Salt Lakes Project comprise an internationally significant Project in the SOP sector, potentially sustaining one of the globe’s largest SOP production operations for many decades. The lakes in the Goldfields Salt Lakes Project were chosen for scale, potential brine volume, known hypersaline brine characteristics, and the potential for production from shallow trenches and deeper paleochannel aquifer bores.

Salt Lake Potash’s Marketing Strategy is a global diversification approach involving market penetration to establish premium product acceptance, and partnering with industry leading offtakers and distributors. It also involves target markets where SO4 SOP has high value-in-use; strategically targeting developed premium markets; and early entry to emerging growth markets.

Salt Lake Potash Limited (WHELF), closed Wednesday's trading session at $0.565, even for the day, on 600 volume. The average volume for the last 3 months is 1,090 and the stock's 52-week low/high is $0.305000007/$0.589999973.

chart

Greene Concepts, Inc. (INKW)

All Cap Research, Street Insider, OTC Dynamics, The WS News Publisher, Investing.com, Simply Wall St, WeTradeHQ, Otc.watch, Stockwatch, Stockopedia, Investingonline.com, Seeking Alpha, TradingView, otcprwire, Dividend Investor, Morningstar, OTC Markets, Wallet Investor, Stockhouse, Globe Newswire, and InvestorsHub reported earlier on Greene Concepts, Inc. (INKW), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Greene Concepts, Inc. is an emerging leader in the worldwide scientifically formulated beverage industry. Via its recently acquired wholly-owned subsidiary, Mammoth Ventures, Inc., the Company has entered into the specialty beverage and bottling business. Greene Concepts lists on the OTC Markets. The Company is headquartered in Clovis, California.

Greene Concepts entered into a definitive agreement on December 28, 2018 to purchase a bottling and beverage facility. This includes land and equipment. The facility will focus on an array of beverage product lines including, but not limited to, CBD (cannabidiol) infused beverages, spring and artesian water, and enhanced athletic drinks in addition to other product offerings.

Greene Concepts has completed the 100 percent acquisition of Mammoth Ventures, Inc., a holding company. The acquisition includes the 60,000 sq. ft. beverage and bottling facility located just outside of Asheville, North Carolina.

This past June, Greene Concepts announced that it expects a near term operations relaunch with pilot production runs debuting high margin specialty and enhanced beverages targeted for the $93.68 billion worldwide functional drinks market. In preparation for an operations relaunch at the plant, a 30-plus year veteran of the bottling industry was appointed plant manager to supervise all renovations.

Recently, Greene Concepts updated shareholders that water purity standards far surpassing industry norms have been implemented at its bottling facility in Marion, North Carolina. The worldwide bottled water industry is forecast to reach $215.12 billion by 2025, according to Grand View Research, Inc. Beverage Marketing corporation projects within the next few years, individual consumers will drink greater than 50 gallons of bottled water annually.

Karen Howard, Chief Executive Officer of Greene Concepts, said, “As our bottling facility approaches relaunch, we are committed to bottling the cleanest water possible, and test to the highest standard for arsenic of no more than .005 mg/liter, the equivalent of 5ppb. The FDA standard is 10ppb.”

Greene Concepts, Inc. (INKW), closed Wednesday's trading session at $0.0055, up 52.7778%, on 5,059,626 volume with 86 trades. The average volume for the last 3 months is 4,606,619 and the stock's 52-week low/high is $0.002099999/$0.049499999.

chart

Relmada Therapeutics, Inc. (RLMD)

NetworkNewsWire, OTC Markets, Wallet Investor, Capital Cube, Real Investment Advice, Zacks, Super Stock Screener, Simply Wall St, Market Screener, Equities, Trading View, Marketbeat, Street Insider, Stockhouse, Streetwise Reports, MarketWatch, and InvestorsHub reported previously on Relmada Therapeutics, Inc. (RLMD), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Relmada Therapeutics, Inc. is developing REL-1017 (dextromethadone) in manifold indications. RELM-1017 is in Phase 2 for treatment resistant depression and preclinical testing for additional indications. In essence, Relmada Therapeutics develops novel therapies for the treatment of central nervous system (CNS) diseases. A clinical-stage company, Relmada Therapeutics lists on the OTC Markets Group’s OTCQB. The Company is headquartered in New York, New York.

The expectation is that Relmada Thereapeutics’ approach will reduce clinical development risks and costs. This is while potentially delivering valuable products to address areas of high unmet medical needs.

The Company’s lead program is the above-mentioned dextromethadone (REL-1017). This is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with an array of cognitive, neurological, as well as behavioral symptoms.

Relmada is targeting major advances in the treatment of CNS disorders. At present, REL-1017 is in a Phase 2a trial for the treatment of Major Depressive Disorder (MDD). Furthermore, there is considerable potential in numerous additional indications. This includes Rett Syndrome.

Relmada Therapeutics also has additional valuable pipeline assets for partnering. These include REL-1015 Levocap ER – a Phase 3-ready abuse deterrent formulation of a highly-potent opioid. Assets also include REL-1028 BuTab - an oral formulation of modified release buprenorphine for chronic pain. Additionally, assets include REL-1021 MepiGel – a novel topical version of local anesthetic mepivacaine for the treatment of painful peripheral neuropathies.

Recently, Relmada Therapeutics announced that the last subject completed dosing with REL-1017 (dextromethadone) in the Company's double-blind, placebo-controlled Phase 2 clinical study evaluating the safety and efficacy of REL-1017 as an adjunctive treatment in patients affected by treatment-resistant depression. Relmada expects to announce topline results from the study in Q3 of 2019.

The Phase 2 study of REL-1017 in treatment resistant depression is a Phase 2, multicenter, randomized, double-blind, placebo-controlled 3-arm study. This study is to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients diagnosed with Major Depressive Disorder (MDD). Subjects in the study are adults with MDD who have experienced an inadequate response to one to three courses of treatment with an antidepressant medication. The study enrolled 62 subjects at approximately 10 sites in the U.S.

Relmada Therapeutics, Inc. (RLMD), closed Wednesday's trading session at $47.18, up 36.9124%, on 1,394,326 volume with 9,510 trades. The average volume for the last 3 months is 101,781 and the stock's 52-week low/high is $4.40000009/$48.00.

chart

Rokk3r, Inc. (ROKK)

Invest Tribune, Dividend Investor, Market Screener, Investors Hangout, Stockopedia, Wallet Investor, Barchart, Stockhouse, Simply Wall St, MarketWatch, InvestorsHub, Stockwatch, Street Insider, and PR Newswire reported earlier on Rokk3r, Inc. (ROKK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Rokk3r, Inc. is an international idea-to-exit company builder listed on the OTC Markets. The design of the Company’s services are to leverage exponential technologies to quickly accelerate and shape industries. Its ecosystem approach aims to lessen friction and streamline execution through taking advantage of talent, shared services, experience, and networks. Rokk3r has its corporate headquarters in Miami, Florida.

The Company provides a set of services that is a hybrid network of human and machine intelligence systems, seeking to enable early stage start-up technology companies and existing businesses to develop new products and businesses in a frictionless, accelerated and complete way. The exponential technologies include artificial intelligence (AI), augmented and virtual reality (AR, VR), blockchain (decentralized ledger technologies), data science, digital biology and biotech, machine learning, nanotech, robotics and sensors.

Rokk3r works to optimize rates of success in company building and product development through offering a wider range of essential services in one place. From business diagnosis to strategy design, execution and funding, the Company helps organizations and ventures augment and transform exponentially.

Regarding its Global Idea-to-Exit Ecosystem, Rokk3r de-risks and democratizes company building via a blockchain based platform that leverages a hybrid of human and machine intelligence. The Company is unleashing the next generation of worldwide entrepreneurship through providing access to education, idea validation, team creation and experts to crowd build successful ventures.

Rokk3r is the newest affiliate of Techstars, the global network that helps entrepreneurs succeed. The entities' affiliate relationship grants Rokk3r-referred start-ups, including Rokk3r's portfolio of over 40 companies, and expedited entry to Techstars' accelerator network, among other benefits.

Techstars founders and their teams connect with other entrepreneurs, experts, mentors, alumni, investors, community leaders, and corporate partners who will help their companies grow. Techstars operates three divisions. These are Techstars Startup Programs, Techstars Mentorship-Driven Accelerator Programs, and Techstars Corporate Innovation Partnerships.

Rokk3r, Inc. (ROKK), closed Wednesday's trading session at $0.58875, up 83.9844%, on 100 volume with 1 trade. The average volume for the last 3 months is 4,072 and the stock's 52-week low/high is $0.319999992/$2.00.

chart

Northern Minerals & Exploration Ltd. (NMEX)

Club Penny Stocks Network, OTPicks, OTCBB Journal, Orbit Stocks, Northern Miner, SmallCapVoice, Proactive Investors, Penny Stock Tweets, Mining Feeds, MarketWatch, TopPennyStockMovers, First Penny Picks, InvestorsHub, Marketwired, Junior Mining Network, OTC Markets, Wallet Investor, 4-Traders, and Stockhouse reported earlier on Northern Minerals & Exploration Ltd. (NMEX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Northern Minerals & Exploration Ltd. is a natural resource company listed on the OTC Markets. Its focus is on oil and gas exploration & production in Texas, gold & silver exploration in Nevada, and hotel & resort development in Mexico. The Company previously went by the name Punchline Resources Ltd. It changed its corporate name to Northern Minerals & Exploration Ltd. in August of 2013. Northern Minerals & Exploration is based in Salt Lake City, Utah.

In 2017, Northern entered into a Letter of Intent (LOI) with a private Mexican entity to work together and conduct due diligence for participating in projects in Mexico with an initial emphasis on a property in the State of Quintana Roo. This Property is a part of the Riviera Maya. It is near the earlier discovered Ichkabal Mayan ruins. It is positioned on the Caribbean coast of the Yucatan Peninsula. The Company considers the Property to have considerable potential for resort development.

Northern Minerals & Exploration has established a Mexican Subsidiary - Enmex Operaciones for Real Estate Development Projects in Mexico. In addition, the Company created Kathis Energy LLC, as a wholly-owned subsidiary. Kathis is establishing oil and gas operations in west and south Texas.

Furthermore, Northern Minerals & Exploration recently announced the signing of a Memorandum of Understanding (MOU) with Labrador Capital SAPI De CV on March 8, 2019. This is the initial step toward entering into a Joint Venture (JV) Agreement for pursuing real estate development opportunities in the Puerto Morelos region of the Yucatan Peninsula of Mexico with Labrador.

Labrador has successfully developed real estate projects in Mexico, particularly in Puerto Morelos, considered to be the Mexican Riviera in the State of Quintana Roo. Labrador is a significant shareholder of Northern Minerals & Exploration and its President is Mr. Victor Miranda, who also serves as the Company’s Chief Financial Officer.

Northern Minerals & Exploration Ltd. (NMEX), closed Wednesday's trading session at $0.068, up 106.0606%, on 9,000 volume with 1 trade. The average volume for the last 3 months is 2,960 and the stock's 52-week low/high is $0.027499999/$0.119999997.

chart

SusGlobal Energy Corp. (SNRG)

Simply Wall St, Penny Stock Hub, Trading View, Wallstreet Online, Market Screener, Dividend Investor, Barchart, Investors Hangout, Stocks News Feed, GuruFocus, Street Insider, Interactive Brokers, Law Insider, last10k, YCharts, Morningstar, and MarketWatch reported on SusGlobal Energy Corp. (SNRG), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

SusGlobal Energy Corp. is the developer of SusGro™, which is a pioneering pathogen free organic fertilizer. The Company is a renewables business centered on acquiring, developing, and monetizing a portfolio of proprietary technologies in the waste to energy and regenerative products application worldwide. SusGlobal Energy has its head office in Toronto, Ontario. The Company lists on the OTC Markets Group’s OTCQB.

SusGlobal Energy has the capability to provide a complete range of services for handling organic residuals. The Company has spent years attaining proprietary processes and combining different treatments. It also has many years of innovative experience and technical knowledge and thus can provide its clients with comprehensive solutions. SusGlobal Energy has projects in Belleville, Ontario; Hamilton, Ontario; and Florida.

SusGlobal Energy can, from beginning to end, offer in-depth knowledge, abundant experience and trailblazing technology for all a client’s needs in handling organic waste. Some of the Company’s work managing organic waste streams includes Anaerobic Digestion, Dry Digestion, Biogas Production, Wastewater Treatment, In-Vessel Composting, Source Separated Organics Treatment, Biosolids Heat Treatment and Composting.

The Company’s SusGro™ pathogen free organic fertilizer offers an economical, sustainable and highly effective alternative to traditional fertilization. SusGro™ is an organically-based, concentrated organic pathogen free liquid fertilizer product. It has a full complement of nutrients suitable for a broad spectrum of fertilization requirements.

In addition, SusGlobal Energy’s Earth’s Journey™ Compost enhances plant growth. The Company employs patented technology to transform organic waste into the most nutrient-rich organic compost, diverting organic waste from landfills and lessening Greenhouse Gas (GHG) emissions.

Recently, SusGlobal Energy announced that its wholly-owned subsidiary, SusGlobal Energy Belleville Ltd. (SusGlobal Belleville), executed a non-binding Letter of Intent (LOI) for certain assets, including 39.44 acres of property located at 704 Phillipston Road, in Belleville, Ontario. Subject to the execution of an Asset Purchase Agreement (APA), the LOI sets out the terms, including the purchase price of USD$1,332,153 (CAD$1,767,250) in cash to be paid on closing, minus the sum of USD$54,274 (CAD$72,000) advanced by SusGlobal Energy to the seller on February 5, 2019.

If the APA is signed, SusGlobal Belleville will become the owner of the 39.44 land parcel and no more a lessee of the existing 13.88-acre section. SusGlobal Belleville will be expanding the site capacity to 70,000 tonnes per annum from the present 35,000 tonnes per annum composting facility to continue producing its Earth's Journey™ Compost, with an additional 50,000 tonnes per annum organic processing and transfer site approved under the existing Environmental Compliance Approval (ECA) and Site Plan.

Mr. Marc Hazout, Executive Chairman and President of SusGlobal Energy, stated, "We are very pleased to be able to enter into an LOI to purchase this large parcel of land with the ECA attached in order to expand our Belleville site to bring the Ontario, Quebec and New York State organic waste management systems to a sustainable level by diverting from landfills."

SusGlobal Energy Corp. (SNRG), closed Wednesday's trading session at $0.055, up 37.50%, on 6,100 volume with 4 trades. The average volume for the last 3 months is 70,707 and the stock's 52-week low/high is $0.030999999/$5.00.

chart

Black Sea Copper & Gold Corp. (BLSSF)

Stockhouse, Market Screener, InvestorsHub, MarketWatch, GuruFocus, Wallet Investor, Barchart, Investors Hangout, and Dividend Investor reported earlier on Black Sea Copper & Gold Corp. (BLSSF), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

Black Sea Copper & Gold Corp. is a mineral exploration company that is active in the Black Sea region of Eastern Europe. Its commitment is to build a strong portfolio of high quality copper and gold projects with the potential to become world-class mining assets. Black Sea Copper & Gold has established a complement of local technical, logistical, community, and corporate support. The Company is headquartered in Vancouver, British Columbia and trade on the OTC Markets.

Black Sea’s mission is to quickly grow and advance a successful portfolio of projects in the West Tethyan Metallogenic Belt of Eastern Europe through discovery, acquisitions, and partnerships. Its projects include  Kalabak, Copper-Gold; and Zlatusha, Copper-Gold.

Black Sea Copper & Gold has demonstrated its ability to identify new copper-gold porphyry and epithermal targets. The Company believes that it has one of the most extensive proprietary geological/exploration databases for Eastern Europe in the industry. Black Sea has more than four years of regional experience technically and operationally within Bulgaria, Serbia, Turkey, and Romania.

Kalabak (100 percent owned) is about 10 km north of Ada Tepe in the Bulgarian Rhodope Mountains. Mineral potential at Kalabak was identified during Black Sea’s extensive reconnaissance exploration program in Bulgaria. As a result, the Company applied for and was awarded the Kalabak license in October of 2014. The Kalabak license area (191 km2) lies within a developing porphyry copper-gold belt in the southeastern sector of the Bulgarian Rhodope Mountains. 

Zlatusha is approximately 40 kilometers northwest of Sofia in western Bulgaria within the Srednogorie endowed arc segment of the West Tethyan Metallogenic Belt. The Zlatusha license area (195 km2) lies within a developing porphyry copper-gold/epithermal belt situated northwest of Sofia.

Black Sea Copper & Gold’s project pipeline includes Golaka, Copper-Gold, which is roughly 1 km from the Assarel Mine in the Panagyurishte Cu-Au trend in central Bulgaria. In addition, the Company’s project pipeline includes Coka Njalta, Copper-Gold, positioned approximately 5 km south of the Majdanpek Mine in the world-class Timok belt of eastern Serbia.

Black Sea’s project pipeline also includes Susulajka, Copper-Gold. This project is 12 km north of the Bor Mine in the world-class Timok belt of eastern Serbia.

Recently, Black Sea Copper & Gold announced it received its exploration and prospecting license from the Ministry of Energy for its 100 percent owned Zlatusha project. The exploration program conducted to date (as of September 27, 2018) by Black Sea has improved the understanding of the known target areas and has yielded numerous additional target areas. The 7 target areas are based on alteration/sulphide/oxide zones in conjunction with anomalous copper and gold.

Black Sea Copper & Gold Corp. (BLSSF), closed Wednesday's trading session at $0.018, off by 12.1951%, on 2,856 volume with 4 trades. The average volume for the last 3 months is 1,176 and the stock's 52-week low/high is $0.009999999/$0.079999998.

chart

Metrospaces, Inc. (MSPC)

Stockwolf, Investors Hangout, Street Insider, Penny Stock Tweets, Stockhouse, Stock of the Week, InvestorsHub, OTC Markets, ClayTrader, Small Cap Network, Insider Financial, Barchart, WalletInvestor, MarketWatch, Emerging Growth, and Street Register reported earlier on Metrospaces, Inc. (MSPC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Metrospaces, Inc. is a real estate investment and development Company. It acquires land, designs builds, and develops, then resells condominiums and Luxury High-End Hotels, chiefly in urban areas of Latin America. The Company is operated by a premier group of real estate and investment professionals and entrepreneurs located in New York, New York; Miami, Florida; and Buenos Aires, Argentina. Metrospaces’ current projects are in Buenos Aires, Argentina, and Caracas, Venezuela.

A start-up real estate private equity firm, Metrospaces is based in New York City. The Company’s refocusing of its business plan to U.S.-based projects is now complete. Metrospaces has strong relationships with Investment Bankers, Real Estate Entrepreneurs, Political Leaders and High Net-Worth Individuals around the world. The Company’s focus is on mid-sized deals. Metrospaces looks to use its international relationships in financing and real estate developers to find co-investment and development opportunities in home building, residential and hotel. Furthermore, it will invest in operating companies that are real estate based. This includes hotel operators and senior facilities operators. Metrospaces will also invest in corporate reorganization.

The Company focuses on joint ventures (JV’s) with established players. Metrospaces’ majority shareholders have partnered with Investors on elite properties including The London BLVGARI 5 Star Hotel and are presently involved in negotiations for the development of a number of elite luxury properties in South America.

Metrospaces has executed a JV Agreement with Prohotels of Argentina. The agreement calls for the development of four new hotels in the coming three years.

Recently, Metrospaces announced a management decision to focus capital resources to its Cannabis-related real estate Company, CannPartners. At present, Metrospaces is looking at two properties, one in Connecticut and one in California. The Company is also keeping a strong focus on the New York market. It is in advanced talks for acquisition of those properties.

Mr. Oscar Brito, Metrospaces Executive President, said, “The continuing legalization of medical and recreational cannabis growing and distribution will continue in the US for the foreseeable future. Many investors are focusing on the grow, distribution and ancillary industries such as paraphernalia etc. However, even with the billions of dollars currently being invested in the cannabis industry, there are very few institutional investors solely focusing on the cannabis-related real estate side of the business. In our opinion, this represents a once-in-a-generation opportunity to buy distressed and real estate located in out-of-favor locations across the U.S.”

Metrospaces, Inc. (MSPC), closed Wednesday's trading session at $0.0001, up 9,900.00%, on 3,635,000 volume with 5 trades. The average volume for the last 3 months is 11,461,849 and the stock's 52-week low/high is $0.000000999/$0.0006.

chart

The QualityStocks Company Corner

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven, precision-medicine company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery. An article discussing the company reads, “POAI’s platform, composed of over 150,000 patient tumors, harnesses the power of an individual patient’s tumor to help recommend the best treatment for that patient. To view the full article, visit http://nnw.fm/2sEFv.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Wednesday's trading session at $2.82, up 5.0866%, on 80,884 volume with 392 trades. The average volume for the last 3 months is 19,765 and the stock's 52-week low/high is $2.3499999/$8.50.

Recent News

chart

GP Solutions (OTC: GWPD)

The QualityStocks Daily Newsletter would like to spotlight GP Solutions (GWPD).

GP Solutions (OTC: GWPD), the developer of modular automated micro-farms, may help in solving the E.coli crisis that is sickening dozens across America according to Business Management News. Per the article, dozens of people were infected across 19 states in the most recent E. coli outbreak stemming from lettuce harvested in California. Of those infected, their ages range from 3 to 89 years old, with 39 requiring hospitalization and six developing kidney failure. To view the full press release, visit http://nnw.fm/GRx07.

GP Solutions (OTC: GWPD) is developing scalable farming systems for soil-less indoor organic farming. The company’s GrowPods are automated micro-farms that use hydroponic technology and unique soil systems to cultivate the highest-quality specialty leaf crops. The system is designed and engineered for ease of use, allowing users to farm year-round in any location of the world, supporting the company’s mission to provide customers with the ability to cultivate their own organic “superfoods.”

GrowPod Design & Function

GrowPod is a modular, stackable and mobile vertical growing environment specifically engineered to maximize yield and automation. GrowPods are available as a vertical pod, stacker pod or custom-built pod.

The Stacker Pod is a certified organic soil system that offers growers multiple levels of planting in order to maximize space and produce options with different fruits and vegetables. The Vertical Pod utilizes a vertical hydroponic system. It is affordable, scalable, efficient, automated and sustainable. The output provides customers with fresh and clean produce year-round in any climate. The Custom Pod is built to suit the farmer’s specific crop and grow goals.

Each 320-square-foot GrowPod container will have an annual production capability of up to four times that of outdoor growing methods, dramatically increasing profitability to the grower. The controlled environment of the GrowPod ensures efficient power and water usage in growing a wide range of horticultural and agricultural products in all environments and climates.

Thanks to a combination of hydroponic and certified organic soil systems, crop yields are higher, faster, and more consistent that conventional means. Customers can enjoy an average of eight higher yield crop cycles anywhere in the world.

GrowPod Features:

  • Modular, stackable and mobile
  • Fully insulated, food-grade shipping container
  • Engineered for automation
  • Efficient LED lighting
  • Hydroponic or soil-based platforms
  • Proprietary air and water filtration
  • Climate-controlled
  • Remote monitoring

GP Solutions also offers many services to its customers, including:

  • Shipment and installation service of its shipping container farms
  • On-site training
  • Provision of custom planting and harvesting schedule
  • Provision of growing supplies, seeds, nutrients, packaging, branding and repair materials
  • On-site visits, on-call and scheduled maintenance, and re-supply
  • Remote monitoring and automated control of environmental nutrients, environmental growth factors (PH, temperature, light) and circulation
  • Technical assistance
  • Consulting and custom facility systems design

Competitive Advantage

GrowPods allow cultivation to take place year-round, which maximizes ROI. The systems are sealed from outside pathogens, contaminants, pesticides, and the result is clean and robust crop production.

GP Solutions also has a line of remarkable new proprietary soil mixtures and nutrient lines which contain no animal products. These products are vital, as many other soils and additives can contain harmful pathogens and contaminants that can cause crops to become tainted or fail rigorous testing.

Global Solution

GP Solutions has partnered with the world’s leading food nonprofit companies, including Feeding America, Seeds of Hope, Habitat for Humanity, Meals on Wheels America, L.A. Kitchen, and Farm Bread, to help insecure communities take control of their own food dependence using container farms.

GP Solutions (GWPD), closed Wednesday's trading session at $1.50, up 150.00%, on 2,990 volume with 8 trades. The average volume for the last 3 months is 10,453 and the stock's 52-week low/high is $0.600000023/$21.00.

Recent News

chart

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a digital marketing and consumer data management technology company, today announced its partnership with Cint to leverage the BIGtoken platform to gather insights for brands. According to the update, Cint has the world's largest online sample exchange, and its platform automates sample fieldwork and operations for insights companies to gather research data faster, more cost-effectively and at scale. To view the full press release, visit http://nnw.fm/9Us1F.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday's trading session at $1.2697, up 1.0908%, on 234,418 volume with 722 trades. The average volume for the last 3 months is 102,117 and the stock's 52-week low/high is $1.12999999/$5.8499999.

Recent News

chart

Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF).

Willow Biosciences (CSE: WLLW) (OTCQB: CANSF) on Tuesday announced its receipt of final approval to list its common shares on the Toronto Stock Exchange (the "TSX"). According to the update, Willow’s common shares will commence trading on the TSX effective as of the open of the market on Thursday, December 5, 2019. The common shares will continue to trade under the symbol "WLLW" upon listing on the TSX. In conjunction with the TSX listing, the common shares will concurrently be delisted from the Canadian Securities Exchange. To view the full press release, visit http://cnw.fm/il5AE.

Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (OTCQB: CANSF), closed Wednesday's trading session at $0.47297, up 7.4932%, on 700 volume with 4 trades. The average volume for the last 3 months is 7,943 and the stock's 52-week low/high is $0.423999994/$2.1775.

Recent News

chart

HTC Extraction Systems (TSX.V: HTC)

The QualityStocks Daily Newsletter would like to spotlight HTC Extraction Systems (TSX.V: HTC).

With the acquisition of a company engaged in the extraction, purification and wholesale distribution of hemp-based cannabinoid extracts, HTC Extraction Systems (TSX.V: HTC) has bolstered its output capability and institutional knowledge considerably. The acquired entity – Kase Farma Inc. of Ceres, California – is currently expanding and upgrading its extraction, refining and processing operations. Kase Farma will enter into an intellectual property licensing agreement with Starling Brands Inc., the vendor. Under this licensing agreement HTC’s Canadian facility will also be the recipient of this intellectual property (http://cnw.fm/Jn1p3).

HTC Extraction Systems (TSX.V: HTC) has developed and optimized proprietary technologies designed for biomass extraction, distillation and purification of ethanol and ethanol-based solvents used for the hemp biomass and cannabidiol (“CBD”) industry, as well as gas and liquid extraction. HTC’s extraction & purification systems are engineered to large-scale to reduce capital and operating costs while delivering superior performance measured by reduced energy usage, lowered emissions and improved quality of the product produced.

Advanced Extraction Technologies

For more than 14 years, HTC has developed and optimized proprietary technology and purification systems used for biomass, gas and liquid extraction. These technologies include:

  • LCDesign® – Low-cost design for modular gas, liquid and biomass extraction systems optimizes plant design, thus reducing capital and operating costs.
  • PDOEngine™ – Software-based design algorithms accurately model and simulate gas, liquid and biomass extraction processing.
  • Delta Solvents™ – Custom-designed, ethanol-based solvent mixtures and additives that optimize production and reduce costs. Technology development is being conducted at HTC’s sponsored research facilities at the University of Calgary.

Delta Purification® Technology

HTC’s patented Delta Purification® technology will purify, recycle and reuse the extraction ethanol used in the CBD extraction process while managing and reducing any CBD waste losses through the re-extraction of all wastes collected from the purified ethanol. Current and new technologies include:

  • Delta CBD Reclaiming System: Reclaiming and purifying ethanol for use in CBD extraction from biomass. Reduces required heat to prevent damage of the chemical attributes of the CBD molecule, allowing extracted CBD to meet food-grade targets for human consumption.
  • Delta Solvent Reclaiming System: Reclaiming and purifying ethanol-based solvents, such as single, mixed and formulated amines, for use in natural gas processing and post-combustion CO2 capturing processes.
  • Delta Glycol Reclaiming System: Reclaiming and purifying glycols, such as mono-ethylene glycol and tri-ethylene glycol for use in natural gas dehydration processes.

Hemp Biomass and Tolling Contracts

HTC has entered into a hemp biomass tolling agreement for the 2019 crop year involving a supply of hemp biomass from a hemp grower in Saskatchewan, Canada. The hemp grower utilizes five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process and extract CBD FSO distillate from the hemp biomass. As a tolling fee payment, HTC will receive a percentage of the extracted CBD FSO distillate for its processing, extraction, purification and distillation services.

Additional hemp biomass tolling contracts with producers and hemp biomass providers are being negotiated in the U.S. for the 2020 hemp crop growing year. HTC will provide “local-to-grower” drying-to-biomass storage capability and transportation of dried biomass to an HTC, location to be determined, future US based, extraction facility. HTC is also in negotiation with a 60,000-acre, recognized Canadian farm leader, who is a significant hemp biomass producer, for a similar hemp biomass tolling contract.

re3™ Technology

Large users of ethanol and solvents for plant oil extraction demand reduced capital and operating costs. HTC’s re3™ (reclaim, recycle, reuse) technology can save up to 30% of the required fluid costs. The increasing cost of new extraction ethanol, combined with the cost of used ethanol disposal, creates a unique opportunity whereby the re3™ technology will create cost savings, while meeting environmental responsibilities.

The growth of ethanol and CO2 used in CBD production has created a new demand for reliable commercial scale ethanol reclaimer systems. The Delta Purification® ethanol system meets this new demand.

Sales and Offtake Agreements

HTC intends to leverage its relationship with its related entity, Purely Canada Foods™, to provide sales and distribution for its Ingredient CBD market under the brand of Purely Canada Hemp™, Purely Canada CBD™, Purely Canada Cannabinoids™. Purely Canada Hemp™ will develop risk managed multi-year ingredient supply contracts with its existing and new Global Food, Beverage and Animal Food Industry Customers.

Project Construction

HTC has focused the Canadian implementation of its BOOM (build, own, operate and maintain) extraction tolling strategy on a location near Regina, Saskatchewan. HTC is currently constructing a 19,000-square-foot GMP Euro compliant extraction tolling facility on six acres of land that will include biomass processing, extraction, implementation of DeltaSolv™ technologies and Delta Purification® systems, distillate and refining equipment, laboratory quality control and testing operations, and on-site office and admin facilities.

Leadership

Chairman, CEO and Director Lionel Kambeitz is a recognized professional in business development and international business relations. He has played a founding role in many other Canadian and U.S.-based companies. Kambeitz has executive experience in a variety of industries including energy, agriculture, food production engineering, and manufacturing.

Jeff Allison, Senior Vice President, Chief Financial Officer and Director, has over 20 years of experience in corporate finance and business development. Prior to joining HTC in 2005, Allison as Vice President assisted with the founding and setup of CUCORP Financial Services in Saskatchewan.

HTC Extraction Systems (TSX.V: HTC), closed Wednesday's trading session at $0.205, up 13.8889%, on 175,095 volume with 56 trades. The average volume for the last 3 months is 128,859 and the stock's 52-week low/high is $0.079999998/$1.24.

Recent News

chart

No Borders Inc. (OTC: NBDR)

The QualityStocks Daily Newsletter would like to spotlight No Borders Inc. (NBDR).

No Borders Inc. (OTC: NBDR), a multifaceted corporation specializing in the acquisition, creation and scaling of commercial and consumer products by utilizing cutting edge technologies to reduce costs while increasing revenues and shareholder value, has launched a revolutionary blockchain utilization platform specifically designed for the CBD industry. No Borders CEO and Chairman Joseph Snyder recently presented the company’s CBD LabChain platform to a wide audience of industry leaders and professionals attending Blockchain Expo 2019 in San Francisco (http://ccw.fm/Oc29w). Also today, the company was highlighted in a publication from HempWireNews, examining how hemp’s versatility is almost mind-boggling. Said to have more than 2000 uses, the amount of things you could do with hemp seems almost endless. It can be used to make a variety of industrial products such as rope, textiles, and bioplastics, but did you know hemp can also be used to make clothes? It is a strong, versatile and cost-effective alternative, and it has been used to make fabric for thousands of years.

No Borders Inc. (OTCQB: NBDR) specializes in the acquisition, creation and scaling of commercial products by utilizing cutting-edge technologies designed to reduce costs while increasing revenues and shareholder value. With active subsidiaries in healthcare, education, cannabidiol (CBD), finance and technology, No Borders is uniquely positioned to use its expertise to improve margins and add business lines within target verticals. No Borders is headquartered in Arizona with remote work resources in the U.S., South America, Asia and Europe.

Different by Design

Deeply experienced at actionable data compilation, analysis and utilization, No Borders believes that data utilization in a Web 3 ecosystem of predictive analytics, blockchains, consensus algorithms, IoT and 5G are vital keys to the future of disrupting global business.

The company leverages its technological talent and visionary approach alongside best-in-class branding, messaging and product teams to simultaneously deploy multiple vertical product offerings at the same time.

With resources around the world, No Borders operates as a 100% remote work, lean operating organization with a founding ideological focus on “Lifestyle by Design.” No Borders’ teams are built by allowing people to work when they want and from where they want as long as deliverables and results are achieved. This structure allows for strategic talent acquisition without the need for relocation or commuting; lowered operating and fixed costs; as well as improved morale and substantially increased staff productivity.

NBDR Companies

  • No Borders Dental Resources Inc. provides equipment and supplies to medical and dental professionals across the U.S. through the trade name, MediDent Supplies. MediDent has a strategic focus on expanding product portfolios and optimizing lifetime customer value while minimizing customer acquisition cost in the medical, dental and veterinary spaces.
  • No Borders Naturals is a purveyor of health and wellness products for active consumers and their pets. No Borders Naturals aims to be an industry leader in alternative wellness product offerings and is currently expanding its digital offering with impactful product up-sell opportunities such as a series of “Buy Two-Get One” on products on its 1000mg CBD tincture, collagen and retinol beauty cream.
  • No Borders Labs Inc. provides leading-edge tech tools to the No Borders family of companies along with building, testing and deploying technology solutions and products to the market while also offering consulting, architecture and software development services to external businesses looking to update their technology infrastructure for greater efficiency, security and transparency.
  • No Borders Funding Inc. provides internal capital and strategic funding options for the family of No Borders companies while actively engaging and networking to find, acquire, structure and deploy unique financial products, solutions and systems with traditional, distributed ledger and blockchain technologies.
  • No Borders Education Inc. provides internal staff training and strategic education tools for the No Borders family of companies while pursuing external revenue generating educational opportunities within the verticals for which No Borders deploys products, services or technologies.

 

Leadership

No Borders CEO Joseph Snyder is a serial entrepreneur whose experiences in real estate investment, financial services and digital strategy over the last 15 years provide a strong, grounded foundation for the structure and ideas outlined in the company’s strategic plan. He brings a unique set of long-term business experiences that provide No Borders with a clear “mile-high” view of the intricately linked systems and challenges associated with growing and scaling our vision.

COO Cynthia Tanabe, a licensed real estate agent/broker since 2004, has successfully built a highly respected investor and bank-focused real estate and property management firm in Arizona with tens of millions of dollars of properties owned and sold.

CTO Chris Brown has 14 years of experience in the IT industry ranging from full stack programming, hardware support, engineering and maintenance, to enterprise-level information system analysis, design, development and implementation. From his background in Air Force intelligence to earning dual B.S. degrees in computational mathematics and biochemistry from Arizona State University, Brown has been engrossed with technologies such as artificial intelligence, machine learning, and decentralized blockchain ledger systems and their connections with real world business applications.

Management is backed by an advisory board with a diverse range of expertise blockchain, brand development, specialty retail, branded consumer products, technology, marketing and other specialties pertinent to No Borders’ growth strategy.

No Borders Inc. (NBDR), closed Wednesday's trading session at $0.026, up 52.9412%, on 467,236 volume with 25 trades. The average volume for the last 3 months is 56,984 and the stock's 52-week low/high is $0.007699999/$0.048799999.

Recent News

chart

Dama Financial

The QualityStocks Daily Newsletter would like to spotlight Dama Financial.

Through a new strategic partnership, Dama Financial is integrating the online banking solution it manages on behalf of its sponsor banks, and its payment processing software Paytender(SM) with PayWana™ self-service technology, Dama Financial announced in a press release (http://nnw.fm/I5lZr). PayWana automated kiosk machines serve as a point-of-sale solution that increase average ticket size, reduce consumer wait times and expenses, and eliminate cash-handling slippage for retail locations nationwide.

Dama Financial, through its bank partners, provides cannabis-related businesses (CRBs) access to transparent, sustainable banking and payment solutions. Using innovative technology, data and artificial intelligence, Dama exceeds the compliance and regulatory requirements for servicing CRBs, bringing legitimacy to the rapidly growing cannabis industry. Dama’s comprehensive and compliant financial framework offers CRBs the option to maintain cashless operations, reducing their exposure to security risks while improving their business efficiencies and operational focus.

Background

As successful fintech entrepreneurs, Dama’s founders have a proven track record of building companies that have removed the barriers that exclude unbanked categories from accessing the fundamental financial solutions necessary to thrive. During the past three years, Dama’s leadership team has turned its focus to addressing the challenges burdening the cannabis industry – the unbanked category of our time.

On behalf of its bank partners, Dama offers access to:

Dama Premier

  • Schedule recurring or ad-hoc appointments for secure cash pick-ups and delivery via armored courier
  • Monitor activity in real time via desktop or mobile or be notified of transaction alerts via email or text
  • Send payments via electronic ACH, wire-transfer or check to approved payees
  • Receive electronic funds from approved partners
  • Transfer money quickly between Dama-managed accounts

CashToTaxSM

  • Schedule secure cash pick-ups and delivery via armored courier
  • Monitor activity in real time via desktop or mobile or be notified of transaction alerts via email or text
  • Send electronic tax payments to approved tax authorities
  • Monitor account activity 24/7 with online and mobile access
  • No minimum balance or account fees

PayMyWaySM

  • Accept electronic retail payments using the secure PayMyWaySM mobile application
  • Customers can fund the app using a linked bank account or debit card at checkout with any PayMyWay merchant
  • Funds settle to the merchant’s PayMyWay Merchant account
  • Integrates seamlessly with any point-of-sale system

All Dama clients enjoy:

  • FDIC insurance on deposits of up to $250,000 per account
  • Dedicated Relationship Manager for account-related inquiries

Dama Financial is an agent of its partnering financial institutions and licensed money transmitters. Customers’ funds will be deposited into a custodial account maintained for the benefit of account holders at one or more FDIC-insured institutions. Fees, terms and conditions apply to depositing funds into and using an Account. Account Terms and Conditions and Fee Schedule are available upon registration to access the online application.


Recent News

chart

MCTC Holdings Inc. (OTC: MCTC)

The QualityStocks Daily Newsletter would like to spotlight MCTC Holdings Inc. (MCTC).

MCTC Holdings Inc. (OTC: MCTC) was featured today in a publication from HempWireNews, examining how hemp’s versatility is almost mind-boggling. Said to have more than 2000 uses, the amount of things you could do with hemp seems almost endless. It can be used to make a variety of industrial products such as rope, textiles, and bioplastics, but did you know hemp can also be used to make clothes? It is a strong, versatile and cost-effective alternative, and it has been used to make fabric for thousands of years.

MCTC Holdings Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

  • Significantly improving bioavailability
  • Allowing for ultra-high loading rates
  • Enhancing customization of cannabinoid combinations
  • Improved dosing precision
  • Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

  • The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
  • Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
  • Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
  • Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

MCTC Holdings Inc. (MCTC), closed Wednesday's trading session at $0.45, even for the day, on 1,854 volume. The average volume for the last 3 months is 13,930 and the stock's 52-week low/high is $0.075000002/$3.00.

Recent News

chart

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International, Inc. (NASDAQ: YGYI) was featured today in a publication from CBDWire, examining how cannabidiol (CBD) has been having a ton of good press over the past few years. Extracted from legal industrial hemp, the compound is choke-full of potent medicinal properties, perfectly capable of kicking a variety of conditions to the curb. The long list of medical conditions CBD is effective against ranges from insomnia and anxiety to severe issues like chronic pain and pediatric epilepsy.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed Wednesday's trading session at $3.91, off by 2.25%, on 48,490 volume with 322 trades. The average volume for the last 3 months is 45,012 and the stock's 52-week low/high is $3.70000004/$9.27999973.

Recent News

chart

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings (NASDAQ: OGI) (TSX: OGI) today announced that it has established an at-the-market equity program (“ATM Program”) that allows the corporation, at its discretion, to issue up to C$55,000,000 (or its U.S. dollar equivalent) of common shares from treasury to the public from time to time. Any common shares sold in the ATM Program will be sold through the Toronto Stock Exchange, the NASDAQ Global Select Market or any other marketplace on which the common shares are listed, quoted or otherwise traded, at the prevailing market price at the time of sale. The corporation, at its sole discretion, will determine the volume and timing of distributions under the ATM Program, if any. To view the full press release, visit http://cnw.fm/fk7Sd. Also today, the company was highlighted in a publication from CBDWire, examining how cannabidiol (CBD) has been having a ton of good press over the past few years. Extracted from legal industrial hemp, the compound is choke-full of potent medicinal properties, perfectly capable of kicking a variety of conditions to the curb.

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Wednesday's trading session at $2.57, off by 9.1873%, on 3,655,595 volume with 10,430 trades. The average volume for the last 3 months is 2,279,614 and the stock's 52-week low/high is $2.00/$8.43999958.

Recent News

chart

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, on Tuesday announced the appointment of accomplished software industry executive Mark K. Ruport as executive chairman and a member of the company's board of directors. To view the full press release, visit http://nnw.fm/vu1yQ. Also today, the company reported its financial and operational results for the third quarter ended Sept. 30, 2019 (http://nnw.fm/8dSvw). The company noted that recent progress with original equipment manufacturers (OEMs), end users and additive-manufacturing integrators positions SGLB for strong revenue growth in 2020.

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Wednesday's trading session at $1.11, off by 0.892857%, on 259,237 volume with 502 trades. The average volume for the last 3 months is 187,256 and the stock's 52-week low/high is $0.451099991/$2.46000003.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

CFN Media (OTCQB: CNFN), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing The Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) and the launch of their new CBD Oil. 2019 has been tough sledding for essentially every public company in the cannabis space. It's not unlike other times over the last decade when high growth stocks, as they are colloquially called, have followed large gains with sharp retractions. While unpleasant for market bulls, it is a normal and healthy part of a cycle, particularly for those industries that are still developing.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Wednesday's trading session at $0.49, off by 1.2296%, on 315,028 volume with 187 trades. The average volume for the last 3 months is 544,910 and the stock's 52-week low/high is $0.432000011/$1.7888.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, is accelerating its patented DehydraTECH based drug delivery technology and formulation development. Funding received from the first tranche of Lexaria’s previously announced private placement of units, issued at a price of $0.45 per unit, realized gross proceeds of $699,410, which will be used to advance several company-wide goals (http://cnw.fm/vJ8up).

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Wednesday's trading session at $0.4111, off by 4.904%, on 105,738 volume with 39 trades. The average volume for the last 3 months is 93,728 and the stock's 52-week low/high is $0.399800002/$1.6875.

Recent News

chart

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF)

The QualityStocks Daily Newsletter would like to spotlight Wonderfilm Media Corporation (OTC: WDRFF).

Wonderfilm Media (TSX.V: WNDR) (OTCQB: WDRFF), a producer of high-quality feature films and episodic television with international appeal, has developed a low risk production process that supports steady, predictable revenues. A recent article discussing the company reads, “Soaring demand for content from streaming providers is fueling industry growth with established media giants in an all-out sprint to dominate some very lucrative revenue streams, a Bloomberg article states (http://nnw.fm/Ch98D). To view the full article, visit http://nnw.fm/iZ0xx.

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF) main business is the worldwide production of high-quality feature films and episodic television. The Wonder?lm team includes Hollywood veterans who have packaged, produced and delivered several profitable recent films, including “BlacKkKlansman,” “Get Out” and “The Hurt Locker.” Having these individuals on the Wonderfilm team demonstrates the company’s proven access to Academy Award-quality films and upside.

Wonder?lm maintains a continuing $58 million annual production slate to meet the constant and growing need for content worldwide. The company’s risk-averse production process results in predictable and consistent revenue streams.

Soaring demand for content from streaming providers is fueling industry growth. The global media and entertainment market is expected to grow from $1.9 trillion in 2017 to $2.4 trillion in 2022, a five-year CAGR of 4.4%.

The company recently formed Wonderfilm Global, an international film and television sales and distribution joint venture that is expected to generate significant incremental revenue.

Wonderfilm has strong relationships throughout the entertainment industry, which enables cost-effective production budgets and in-demand content creation.

Management Team with Proven Track Records

Kirk Shaw: Over 240 movies and seven television series to his credit. Headed up Canada’s largest independent film and television production company, attaining $100 million revenue two years straight with 8% EBITDA.

Dan Grodnik: Founded Mass Hysteria Entertainment, a publicly traded company, and became its chairman/CEO. Produced over 50 feature films, including “Bobby,” the 2006 Robert Kennedy biographic film.

Shaun Redick & Yvette Yates: $300 million+ USD total production budgets to date with a combined 175 award wins/355 nominations, including 10 Oscar nominations. In 2017 and 2018, they produced two of the most successful Hollywood films of those years: “Get Out” ($255 million USD gross revenue) and “BlacKkKlansman” ($100 million USD gross revenue). Scheduled to produce two to three films per year for Wonderfilm, with the first release slated for October 2020. Committed to the 4% challenge to give more women and women of color the opportunity to direct.

Jeff Bowler: 2017 Emmy Award-winning producer. Vice president of acquisitions and production for The Exchange, one of the top film sales and finance companies in the world. Bowler is the executive for Wonderfilm Global distribution.

Bret Saxon: Through his company, TMP Inc., Saxon created M&A deals worth over US$750 million across 113 countries. Produced several feature films and made-for-television movies, including Wonderfilm’s 2019 movie “Zombie Tidal Wave” for NBC/Universal’s SYFY.

17-Title Movie Slate — Greenlit

Wonderfilm currently has 17 films greenlit with combined budgets totaling $58 million. Wonderfilm production stars include: John Travolta, Nicolas Cage, Guy Pearce, Ryan Phillippe and Anne Heche, to name a few.

Some of the company’s most notable greenlit projects include the horror film “Amityville 1974,” slated for theatrical release in October 2020, and the action film “Inside Game” starring Tyrese Gibson, which will be released to theaters in fall 2020.

The company is also actively developing a number of other new IP projects, including a dramatic biographic feature titled “Life and Times of Steve McQueen,” a film adaptation of the bestselling novel “Merchant of Death” and a television series headed by “CSI: Crime Scene Investigation” creator Anthony Zuiker.

 

Potential for Breakout Success

Wonderfilm movies have the potential for millions of dollars in revenue from the kind of breakout success generated by films like “Saw” and “Get Out,” which would propel Wonderfilm and its revenue streams to a new level. Wonderfilm has several potential breakout films in its development/production queue.

Note: Potential breakout films are not factored into company’s revenue projections.

Base Hits and Home Runs

In tandem with its slate of high-profile films, Wonder?lm continues to finance, produce and deliver many profitable low-risk, lower-budget films that are base hits. Shaun Redick is a home run hitter, and his upcoming Wonderfilm projects are anticipated to be home run hits for the company, while base hits such as “Zombie Tidal Wave” provide a consistent source of revenue.

Recent Industry Breakout Films Include:

  • SAW – $1.2 million budget = $103.9 million in sales
  • Pulp Fiction – $8 million budget = $212 million in sales
  • My Big Fat Greek Wedding – $5 million budget = $250 million in sales
  • Lost in Translation – $4 million budget = $120 million in sales
  • Get Out – $4.5 million budget = $255.5 million sales (Shaun Redick)

Note: Revenue from most of Wonderfilm’s current slate will be recorded on the books in 2020 or 2021.

Recent Wonderfilm Releases

  • Aug. 17, 2019: Co-produced with NBC/Universal, “Zombie Tidal Wave” premièred on the SYFY channel to strong ratings.
  • Aug. 29, 2019: “The Fanatic” starring John Travolta opens in U.S. theaters.
  • Sept. 5, 2019: “Tammy’s Always Dying” premiers at Toronto Film Festival.
  • Nov. 8, 2019: “Primal” starring Nicolas Cage opens in U.S. theaters.

Wonderfilm Global Distribution

At the 2019 Cannes Film Festival, Wonderfilm officially launched Wonderfilm Global, a new film, television and media foreign sales/distribution joint venture with 101 Films and Paul McGowan.

Wonderfilm acquired 51% ownership in the joint venture structure and immediately began attaching its own productions to Wonderfilm Global. The joint venture represents a significant opportunity for Wonderfilm, changing how the company does business.

The intention behind Wonderfilm Global is to keep distribution margins in-house that previously went to other companies. Since most Wonderfilm movies are relatively low-risk and easy to sell because they feature desirable cast and genre, third-party distribution companies were previously earning approximately 10%, plus expenses, on Wonderfilm movies without any level of risk. Now, revenue is generated through presales of Wonder?lm projects and, at times, third-party films. The average Wonder?lm movie is pre-sold for $5million, garnering $500,000 to $750,000 per sale as a commission. These commissions now stay in-house with Wonder?lm Global, and the company expects to sell 10 to 12 third-party films between fall 2019 and fall 2020, generating roughly $6 million in commission income.

A further revenue source is generated from theatrical sales through a 50/50 upside split once the minimum sales threshold is met.

Wonder?lm Global has offices in Vancouver, Beverly Hills, London, Ireland, Seoul and China.

Wonderfilm Business Model

Wonderfilm productions are structured to begin generating a return to the company as soon as the camera starts rolling.

Return Before a Film is Delivered: Producer fee line items are included in each production budget. These range from $50,000 to $500,000, depending on the total budget, and are paid to Wonderfilm most commonly on the first day of principle photography.

Distribution: Wonderfilm Global charges sales and distribution fees within each production budget to cover its presale costs.

Note: Wonderfilm’s productions are all structured to minimize risk by matching budget to funds available.

Return After a Film is Delivered: Unsold presale territories are countries or territories left off of a film’s presale list, either for strategic reasons or because the broadcaster/distributor is waiting to see the completed film. These outside-the-budget distribution sales become Wonderfilm profit centers.

Sales overages once contracted presale threshold is surpassed.

The company’s film library grows with each new production, adding to future sales revenue. Depending on the agreement, exploitation rights for future worldwide sales return to Wonderfilm four or seven years after delivery. As of October 2019, Wonderfilm’s growing film library comprises 18 titles for future exploitation.

Note: The nature of the film business is that box office revenue lags production up to a couple of years.

$50 Million Wonderfilm Production Fund (WPF):

Wonderfilm is in the process of raising $50 million to establish a Wonderfilm Production Fund (WPF). WPF is designed to consolidate traditional production financing models into a single diversified, asset-backed debt instrument.

The WPF is a highly specialized investment vehicle with noncorrelated market returns normally reserved for institutional banks and specialty lenders, and it would pay 8% interest directly from each Wonderfilm movie or series budget and not from corporate funds. These same interest payments are already added to each production budget, as the company currently closes a separate financing for every film. The WPF would significantly streamline Wonderfilm’s production rate, adding revenue more quickly and broadening the yearly production slate.

For fund investors, the WPF is a dedicated production-financing vehicle designed to offer a risk-moderated approach to investing in film finance. The managed process provides structure and reassurance that are normally experienced only when working with an institutional lender that has a dedicated staff and resources.

All projects being financed are for Wonderfilm productions, with the fund collateral fully secured by receivables, including presale contracts, government incentives, or a guarantee from Wonderfilm for any unsecured amounts as may be permitted.

Wonderfilm Media Corporation (OTC: WDRFF), closed Wednesday's trading session at $0.0983, off by 1.70%, on 17,147 volume with 7 trades. The average volume for the last 3 months is 41,712 and the stock's 52-week low/high is $0.075099997/$0.462000012.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.